Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature

Figure 2

Evolution of CRP levels on gouty polyarthritis patients () and crowned dens patients associated with peripheral pseudogout or hydroxyapatite deposition disease patients () arthritis under anakinra. Normalization of CRP levels at the 3rd or 5th days for the three polyarthritis gouty patients (grey and dotted lines) associated with complete clinical response and stopping anakinra. Same but later upcoming for two crowned dens syndrome patients (black continue lines), respectively, at the 9th or 11th days of treatment. For the 3rd crowned dens syndrome patient, early cessation of the treatment stopping within the 7–9th days (hatched ellipse) showed reincrease of CRP levels; resuming of anakinra for 11 days showed complete and sustained control of CRP levels and clinical signs.